Compare Prudential Financial Inc (PRU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs BIO-TECHNE Corp — how do they compare? Prudential Financial Inc trades at $113.8 (market cap $39.17B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: Prudential Financial Inc is far larger — about 3.4× BIO-TECHNE Corp's market cap, and Prudential Financial Inc pays the higher dividend (4.93%). Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 145 Days and BIO-TECHNE Corp for 64 Days on average.
| PRU | TECH | |
|---|---|---|
Market Cap | $39.17B | $11.36B |
Volume | 1,436,917 | 5,390,331 |
Sector | Financials | Health |
52-Week High | $125.13 | $72.61 |
52-Week Low | $92.00 | $43.31 |
Typical Hold Time | 145 Days | 64 Days |
Enterprise Value | $67.95B | $11.39B |
Dividend Yield | 4.93% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $113.09, up 0.65% with bearish technical signals but attractive valuation metrics including a P/E of 10.29 and P/S of 0.61. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. The company is executing a strategic overhaul including $3 billion capital rotation and $750 million cost savings while exiting emerging markets through the $185 million Alexforbes sale. Cash flow trends show strong operational performance with $6.3 billion from operations in 2025.
PRU presents a value opportunity with below-market valuations and dividend yield support, though technical weakness and mixed analyst sentiment warrant caution. The strategic refocus on core insurance and wealth management businesses positions the company for improved capital efficiency, while higher interest rates benefit investment income. Key risks include execution challenges in the restructuring and competitive pressures in the insurance sector.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
